Table 2.
Summary of Safety and Tolerability: Incidence of Adverse Effects
| Study | Drug | Nausea/ Vomiting, % | Vision Changes, % | Drowsiness, % | Headache, % | Transient Elevated Blood Pressure, % | Dizziness, % | Dissociation/ Derealization, % | Feeling Cold/ Sensitive to Cold, % | Transient Anxiety/ Distress, % | Hallucinations, % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dos Santos et al, 202170 | Aya | 23.5/17.6 | – | 11.8 | 11.8 | 29.4a | – | 5.9 | – | –/5.9 | – |
| Glue et al, 201762 | Ket | 16.7/– | – | – | – | 100 | – | 100 | – | –/16.7 | – |
| Glue et al, 202064 | Ket | 33.3/16.7 | 91.7 | 66.7 | – | 100 | – | 100 | – | – | – |
| Glue et al, 201863 | Ket | 25.0/– | 22.0 | – | – | 100 | 40 | 50 | – | – | – |
| Taylor et al, 201868 | Ket | 16.7/– | 33.3 | – | – | 11.1a | 33.3 | 38.9 | – | 11.1/– | 16.7 |
| Gasser et al, 201467 | LSD | – | 0 | – | – | 4.5a | – | 9.1 | 45.4 | 22.7/36.4 | 4.5 |
| Gasser et al, 201566 | LSD | – | – | – | – | – | – | – | – | – | – |
| Wolfson et al, 202065 | MDMA | 23.1/– | – | – | 61.5 | – | – | – | 15.4 | 23.1/– | – |
| Grob et al, 201169 | Psi | – | – | – | – | 100 | – | – | – | – | – |
aHypertension defined as blood pressure >140/90 mm Hg.
Note: Missing/unavailable data are indicated with a dash (–).
Aya, ayahuasca; Ket, ketamine; LSD, lysergic acid diethylamide; MDMA, 3,4-methylenedioxymethamphetamine; Psi, psilocybin.